auspexpharma.com
Pipeline | Auspex Pharmaceuticals
http://www.auspexpharma.com/pipeline
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Deuterium-containing pirfenidone analog (SD-560).
auspexpharma.com
News/Events Auspex | Auspex Pharmaceuticals
http://www.auspexpharma.com/news-events
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's disease, Tourette syndrome and tardive dyskinesia. Press Releases / Events. January 01, 1970. 124; read more. January 01, 1970. 124; read more.
auspexpharma.com
Investors | Auspex Pharmaceuticals
http://www.auspexpharma.com/about-auspex/investors
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Auspex Pharmaceuticals’ investors include Thomas, McNerney and Partners, CMEA Capital, Panorama Capital, Sloan Biotech Funds and BioMed Ventures.
auspexpharma.com
For Patients and Families | Huntington's Disease | Auspex Pharmaceuticals
http://www.auspexpharma.com/for-patients-and-family
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's disease, Tourette syndrome and tardive dyskinesia. For Patients and Family. Presentation of SD-809 for the Treatment of Chorea Associated with Huntington's Disease. June 22, 2013. Huntington's Disease Society of America.
auspexpharma.com
Clinical Trials | Huntington's Disease | Auspex Pharmaceuticals
http://www.auspexpharma.com/clinical-trials
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Ongoing Clinical Development of SD-809. Phase 3 placebo-controlled registration trial. Open-label switch and long-term safety clinical trial. Phase 1b clinical trial in Tourette syndrome.
auspexpharma.com
About Auspex | Auspex Pharmaceuticals
http://www.auspexpharma.com/about-auspex
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia.
auspexpharma.com
For Clinicians | Huntington's Disease | Auspex Pharmaceuticals
http://www.auspexpharma.com/for-clinicians
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Clinical Studies for Huntington’s Disease. First Time Use of SD-809 in Huntington Disease (First-HD) read more.
SOCIAL ENGAGEMENT